These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 27534391)

  • 1. Pharmaceutical cost and multimorbidity with type 2 diabetes mellitus using electronic health record data.
    Sancho-Mestre C; Vivas-Consuelo D; Alvis-Estrada L; Romero M; Usó-Talamantes R; Caballer-Tarazona V
    BMC Health Serv Res; 2016 Aug; 16(1):394. PubMed ID: 27534391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The evaluation of clinical and cost outcomes associated with earlier initiation of insulin in patients with type 2 diabetes mellitus.
    Smolen HJ; Murphy DR; Gahn JC; Yu X; Curtis BH
    J Manag Care Spec Pharm; 2014 Sep; 20(9):968-84. PubMed ID: 25166296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Large impact of antidiabetic drug treatment and hospitalizations on economic burden of diabetes mellitus in The Netherlands during 2000 to 2004.
    van der Linden MW; Plat AW; Erkens JA; Emneus M; Herings RM
    Value Health; 2009 Sep; 12(6):909-14. PubMed ID: 19508664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and economic outcomes associated with National Kidney Foundation guideline-concordant oral antidiabetic drug treatment among type 2 diabetes patients with chronic kidney disease.
    Chen SY; Siu K; Kovacs B; Stokes M; Rao P; Sander S; Boulanger L
    Curr Med Res Opin; 2012 Apr; 28(4):493-501. PubMed ID: 22364567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Prevalence of diabetes, antidiabetic treatment and chronic diabetic complications reported by general practitioners].
    Fabian W; Majkowska L; Stefański A; Moleda P
    Przegl Lek; 2005; 62(4):201-5. PubMed ID: 16229234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cost of diabetes mellitus in Spain].
    González P; Faure E; Del Castillo A;
    Med Clin (Barc); 2006 Nov; 127(20):776-84. PubMed ID: 17198665
    [No Abstract]   [Full Text] [Related]  

  • 8. Utilization and cost of drugs for diabetes and its comorbidities and complications in Kuwait.
    Alowayesh MS; Aljunid SM; Al-Adsani A; Alessa T; Alattar A; Alroudhan D
    PLoS One; 2022; 17(6):e0268495. PubMed ID: 35653361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health Care Costs Associated With Macrovascular, Microvascular, and Metabolic Complications of Type 2 Diabetes Across Time: Estimates From a Population-Based Cohort of More Than 0.8 Million Individuals With Up to 15 Years of Follow-up.
    Chen HY; Kuo S; Su PF; Wu JS; Ou HT
    Diabetes Care; 2020 Aug; 43(8):1732-1740. PubMed ID: 32444454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Direct health care costs in patients with type 2 diabetes mellitus six months after starting insulin treatment in Spain: the INSTIGATE study].
    Costi M; Smith H; Reviriego J; Castell C; Goday A; Dilla T
    Endocrinol Nutr; 2011; 58(6):274-82. PubMed ID: 21641287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HBA1C CONTROL AND COST-EFFECTIVENESS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS INITIATED ON CANAGLIFLOZIN OR A GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONIST IN A REAL-WORLD SETTING.
    Wysham CH; Pilon D; Ingham M; Lafeuille MH; Emond B; Kamstra R; Pfeifer M; Lefebvre P
    Endocr Pract; 2018 Mar; 24(3):273-287. PubMed ID: 29547044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cost of the treatments of arterial hypertension associated with diabetes].
    Passa P; Giraud S
    Diabete Metab; 1993 Dec; 19(5 Suppl):523-7. PubMed ID: 8206192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medical expenditures associated with major depressive disorder among privately insured working-age adults with diagnosed diabetes in the United States, 2008.
    Shrestha SS; Zhang P; Li R; Thompson TJ; Chapman DP; Barker L
    Diabetes Res Clin Pract; 2013 Apr; 100(1):102-10. PubMed ID: 23490596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence and coprevalence of chronic comorbid conditions in patients with type 2 diabetes in Catalonia: a population-based cross-sectional study.
    Mata-Cases M; Franch-Nadal J; Real J; Cedenilla M; Mauricio D
    BMJ Open; 2019 Oct; 9(10):e031281. PubMed ID: 31662386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Patient classification and analysis of risk profiles for type 2 diabetics as the main focus point in practice. Results of the TEMPO study].
    Lippmann-Grob B; Bierwirth RA; Kron P; Leinhos B; Funke K; Huptas M; Grüneberg M; Weich KW; Münscher C; Potthoff F
    Dtsch Med Wochenschr; 2004 Jan; 129(3):75-81. PubMed ID: 14724780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health Outcomes Associated with Initiation of Basal Insulin After 1, 2, or ≥ 3 Oral Antidiabetes Drug(s) Among Managed Care Patients with Type 2 Diabetes.
    Levin PA; Zhou S; Gill J; Wei W
    J Manag Care Spec Pharm; 2015 Dec; 21(12):1172-81. PubMed ID: 26679966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The costs of type 2 diabetes mellitus in Italy: a CODE-2 sub-study.
    Lucioni C; Garancini MP; Massi-Benedetti M; Mazzi S; Serra G;
    Treat Endocrinol; 2003; 2(2):121-33. PubMed ID: 15871548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [An analysis of the diabetic population in a Spanish rural are: morbidity profile, use of resources, complications and metabolic control].
    Inoriza JM; Pérez M; Cols M; Sánchez I; Carreras M; Coderch J
    Aten Primaria; 2013 Nov; 45(9):461-75. PubMed ID: 23830042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost effectiveness of insulin glargine plus oral antidiabetes drugs compared with premixed insulin alone in patients with type 2 diabetes mellitus in Canada.
    Tunis SL; Sauriol L; Minshall ME
    Appl Health Econ Health Policy; 2010; 8(4):267-80. PubMed ID: 20578781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug usage patterns and treatment costs in newly-diagnosed type 2 diabetes mellitus cases, 2007 vs 2012: findings from a large US healthcare claims database analysis.
    Weng W; Liang Y; Kimball ES; Hobbs T; Kong S; Sakurada B; Bouchard J
    J Med Econ; 2016 Jul; 19(7):655-62. PubMed ID: 26855139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.